Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035092 | 0.83 | RXRA (0.37) | MAPK14ADORA2AP2RX7RXRANR1H2 | |
| SCHEMBL1033684 | 0.82 | PTGS2 (0.41) | ADORA2ARXRANR1H2NR1H3 | |
| SCHEMBL1033124 | 0.80 | MAPK14 (0.35) | MAPK14ADORA2AP2RX7RXRANR1H2 | |
| SCHEMBL1035131 | 0.80 | NR1H2 (0.39) | ADORA2AP2RX7RXRANR1H2NR1H3 | |
| SCHEMBL1031843 | 0.80 | RXRA (0.42) | CHRM5MAPK14P2RX7RXRANR1H2 | |
| SCHEMBL1034194 | 0.78 | RXRA (0.42) | MAPK14P2RX7RXRANR1H2NR1H3 | |
| SCHEMBL1034738 | 0.77 | RXRA (0.33) | ADORA2ARXRANR1H2NR1H3 | |
| SCHEMBL1033894 | 0.77 | RXRA (0.39) | MAPK14ADORA2AP2RX7RXRANR1H2 | |
| SCHEMBL1033338 | 0.77 | NR1H2 (0.37) | P2RX7RXRANR1H2NR1H3 | |
| SCHEMBL1033495 | 0.77 | RXRA (0.38) | RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1572660-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004058717-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | NR1H2, NR1H3, NR1I2 | CHRM5 702/4885MAPK14 4180/4885ADORA2A 602/4885 |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | NR1H2, NR1I2, NR1H3 | CHRM5 1315/4885MAPK14 4012/4885ADORA2A 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.